Table 3. Therapeutic data for mono- and HCV/HIV-coinfected patients.
| Characteristics | Groups | ||||
|---|---|---|---|---|---|
| Monoinfected (n = 107) | SVR (%) | Coinfected (n = 25) | SVR (%) | ||
| Mean age (years) ± SD | 63.3 ± 9.9 | 95.3 | 56.4 ± 10.4 | 96 | |
| Gender | Female | 62 (58%) | 96.8 | 5 (20%) | 100 |
| Male | 44 (42%) | 93.1 | 20 (80%) | 95 | |
| DAA-naïve patients | 93 (87%) | 95.7% | 24 (96%) | 95.8% | |
| DAA-experienced patients | 14 (13%) | 92.9 | 1 (4%) | 100 | |
| Genotype | 1a | 46 (43%) | 91.3 | 9 (36%) | 100 |
| 1b | 45 (42%) | 100 | 12 (48%) | 100 | |
| 3a | 16 (15%) | 93.8 | 4 (16%) | 75 | |
| Therapeutic regimen/duration (weeks) | SOF + DCV / 12 | 24 (22.4%) | 91.7 | 9 (36%) | 88.9 |
| SOF + DCV / 24 | 1 (0.9%) | 100 | 12 (48%) | 100 | |
| SOF + DCV + RBV / 12 | 62 (58%) | 98.4 | 3 (12%) | 100 | |
| SOF + DCV + RBV / 24 | 20 (18.7%) | 90 | 1 (4%) | 100 | |
| Mean HCV viral load (IU/mL log10) ± SD | 5.7 ± 0.86 | 95.3 | 5.9 ± 0.56 | 96 | |
| Hepatic condition | Cirrhotic | 90 (84%) | 94.4 | 5 (20%) | 80 |
| Non-cirrhotic | 17 (16%) | 100 | 20 (80%) | 100 | |